Zharp1-163

CAT: 0804-HY-178163Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-178163Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Zharp1-163 is a dual inhibitor of ferroptosis and necroptosis. Zharp1-163 effectively blocks ferroptosis by reducing reactive oxygen species (ROS) levels and inhibits necroptosis by potently and selectively targeting RIPK1 kinase activity (KD = 240 nM; IC50 = 406.1 nM) . Zharp1-163 inhibits the cellular activation of RIPK1, RIPK3 and MLKL in response to necroptotic stimulation. Zharp1-163 markedly attenuates TNF-α (HY-P1875) -induced systemic inflammatory syndrome, including the prevention of TNF-α-induced mortality and hypothermia in mice. Zharp1-163 significantly alleviates acute kidney injury associated with both necroptosis and ferroptosis in models induced by Cisplatin (HY-17394) and ischemia-reperfusion. Zharp1-163 can be used for the study of diseases associated with cell death pathways, such as kidney disease[1].
UNSPSC
12352005
Target
Ferroptosis; Mixed Lineage Kinase; Necroptosis; Reactive Oxygen Species (ROS) ; RIP kinase
Related Pathways
Apoptosis; Immunology/Inflammation; MAPK/ERK Pathway; Metabolic Enzyme/Protease; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Smiles
NC1=CN2C(C=CC(C3=CC4=C(N=C3)OCCN4C(OC5CCCCC5)=O)=C2)=N1
Molecular Formula
C21H23N5O3
Molecular Weight
393.44
References & Citations
[1]Ji Y, et al. Discovery of Zharp1-163 as a dual inhibitor of ferroptosis and necroptosis for the treatment of inflammatory disorders and kidney injury. Cell Death Discov. 2025 Aug 28;11 (1) :413.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
RIPK1; RIPK3

Popular Products